drugset / Trial / NCT03058939
Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a two-stage phase II study with a single arm design. It will be conducted in women with breast cancer with stages IIA to IIIC (defined by AJCC 2009 classification) of all histological subtypes. All patients will receive 16 doses of paclitaxel; three breast ultrasound tests and tumor pathologic response evaluation will be used to assess the response to treatment.
Timeline
- Start
- 2018-11
- Primary completion
- 2019-04
- Completion
- 2019-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | — |
| Subject | Paclitaxel | Small molecule | 80 mg/m2 | — |
| Background | Cyclophonsphamide | Unknown | — | — |
| Background | Epirubicin | Small molecule | — | — |
| Background | Letrozole | Other / unclassified | — | — |
| Background | Leuprolide | Other / unclassified | — | — |
| Background | Pertuzumab | Monoclonal antibody | — | — |
| Background | Tamoxifen | Small molecule | — | — |
| Background | Trastuzumab | Monoclonal antibody | — | — |
| Background | fluorouracil | Small molecule | — | — |